PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 4234: Glycan-based site specific ADC achieves sustained tumor control through Improved payload delivery and immune activation

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLiu Chih-ChunTYTsai Yi-ChienHJHuang Jing-rong

Discussion

Loading...

Member takes

Overview

Demonstrates enhanced tumor control with a glycan-based ADC, indicating better immune activation and therapy potential.

Key Points

  • To evaluate the efficacy of a glycan conjugated ADC (OBI-902) in inducing antitumor immunity compared to a cysteine-based ADC (OBI-992).
  • Utilized LL2 syngeneic tumors overexpressing human Trop2 for efficacy assessments.
  • Conducted multiparametric flow cytometry to analyze immune subsets in tumors, lymph nodes, and blood.
  • Measured serum cytokines to evaluate systemic immune activation.
  • OBI-902 achieved sustained tumor growth inhibition and enhanced immunogenic cell death (ICD).
  • Increased CD4+ and CD8+ T-cell infiltration along with elevated serum cytokines (IFN-γ, IL-12, TNF-α).
  • Reduced proportions of myeloid-derived suppressor cells (MDSCs) and improved antigen presentation capabilities observed.

Cite This Study

Chih-Chun et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdf7a79560c99a0a45aahttps://doi.org/10.1158/1538-7445.am2026-4234
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 3149: Development of a novel site-specific ADC glycan platform with potential for improved <i>in vivo</i> efficacy and stability of the ADC in animal studies2024 · 1 citations
  2. 2Abstract 4423: Advancing ADC therapeutics with next-generation site-specific glycan conjugation and dual-payload flexibility2026
  3. 3Abstract 1819: OBI-904, a glycan-based site-specific Nectin-4-targeted ADC, demonstrates potent and durable antitumor activity with an improved PK profile and overcoming EV-resistance in non-clinical studies.2026
  4. 4Abstract 2613: Treatment of solid tumors with antibody drug conjugates targeting aberrant O-glycoproteins2024 · 1 citations
  5. 5Abstract 7179: OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK/PD properties and a favorable safety profile2024 · 2 citations